Researchers studying alternative to bladder removal for bladder cancer patients

A new phase I clinical trial conducted by researchers at the Center for Cancer Research (CCR) is evaluating the safety and tolerability, or the degree to which any side effects can be tolerated by patients, of a two-drug combination as a potential alternative to bladder removal for bladder cancer patients. The trial targets patients with non-muscle invasive bladder cancer (NMIBC) whose cancers have stopped responding to traditional therapies. Read more…

 

Waldmann

Thomas Waldmann named Fellow of the National Academy of Inventors

Posted: Dec 13, 2017

Thomas A. Waldmann, M.D., Co-chief of the Lymphoid Malignancies Branch, has been named a Fellow of the National Academy of Inventors (NAI). According to the NAI, election to NAI fellow status is the highest professional accolade for academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and welfare of society. With the election of the 2017 class there are now 912 NAI Fellows, representing over 250 research universities and governmental and non-profit research institutes. On April 5, 2018, the 2017 NAI Fellows will be inducted as part of the Seventh Annual NAI Conference.  

Thomas Waldmann named Fellow of the National Academy of Inventors
microarrays

Molecular Biology in Single Cells Symposium

Posted: Dec 12, 2017

The symposium is designed to bring investigators to the NIH campus to discuss current advances in fields related to cancer research. This meeting will highlight important advances in the study of cell function through single cell genomics and live cell imaging approaches. The symposium draws investigators from the entire NIH community and many academic institutions throughout the U.S. and abroad.  Learn more...

Molecular Biology in Single Cells Symposium
Target with bullseye

Two-Day Symposium - Frontiers in Targeting MYC: Expression, Regulation and Degradation

Posted: Dec 12, 2017

There is a need for the global community to come together to discuss modern approaches for studying and targeting MYC. Frontiers in Targeting MYC: Expression, Regulation and Degradation is a two-day symposium that will enable the Myc community to come together to discuss problems, approaches and recent results in targeting Myc. Learn more...

Two-Day Symposium - Frontiers in Targeting MYC: Expression, Regulation and Degradation
RNA interactions in viral infections

2018 RNA Interactions in Viral Infections Workshop

Posted: Dec 12, 2017

For more than 70 years, the study of viruses has been at the forefront of molecular biology and cancer biology. Studies done with viruses have provided the foundations of RNA biology including RNA capping, RNA splicing, RNA polyadenylation, RNA transport, cap-independent RNA translation and RNA instability. This workshop will provide a forum in which the most recent progress in protein-RNA interactions in virus infections will be discussed. Learn more...

2018 RNA Interactions in Viral Infections Workshop
Anupama Khare, Ph.D.

Anupama Khare joins CCR as NIH Stadtman Investigator

Posted: Dec 12, 2017

Anupama Khare, Ph.D. has joined the Laboratory of Molecular Biology as a Stadtman Tenure Track Investigator. Dr. Khare's research focuses on understanding how different microbial species co-exist in the same environmental niche and what the molecular interactions in such communities are. She is also interested in studying antibiotic persistence and identifying novel bacterial pathways that can be targeted for antimicrobial therapy in investigating the genetic basis of complex bacterial behaviors in natural environments, with an overarching goal of identifying novel targets for antibiotic therapies. Learn more...

Anupama Khare joins CCR as NIH Stadtman Investigator
Everyday health logo

CCR scientists featured in Cancer Special Report 2017 from Everyday Health

Posted: Dec 7, 2017

In a recent article from Everyday Health, Elizabeth DeVita-Raeburn, Senior Editor of Oncology, details cancer trends in diagnosis, stages, treatment and survival rates. DeVita was one of 12 journalists selected by the Association of Health Care Journalists to attend a week-long reporting fellowship at the National Cancer Institute (NCI) in November 2017 to learn about the latest cancer research and participate in guided tours of NCI wards and labs. Her “Cancer Special Report 2017” discusses the latest immunology work of Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, and Stephanie Goff, M.D., Staff Clinician in the Surgery Branch, gene-expression profiling technique of Louis Staudt, M.D., Ph.D., Co-Chief of the Lymphoid Malignancies Branch, and new Cancer Moonshot efforts to address rare cancers, spearheaded by Mark Gilbert, M.D., Chief of the Neuro-Oncology Branch. Read the full story…

CCR scientists featured in Cancer Special Report 2017 from Everyday Health
Michael Becker

Walking with purpose after an HPV-related head and neck cancer diagnosis

Posted: Dec 6, 2017

In November 2015, Michael Becker was diagnosed with Stage IV head and neck cancer caused by a strain of the human papillomavirus, or HPV. He now advocates for education and awareness of the HPV vaccine as cancer prevention for both boys and girls. “I want to make people aware that you can avoid my situation by getting the shot.” Read more…

Walking with purpose after an HPV-related head and neck cancer diagnosis
Foregut Team

Members of NIH Foregut Team discuss new treatment options for stomach cancer

Posted: Dec 4, 2017

On Wednesday, Nov. 29, 2017, NIH Foregut Team members presented information and answered questions during a webinar on stomach cancer treatment options. Jeremy Davis, M.D., Staff Clinician in the CCR Thoracic and Gastrointestinal Oncology Branch, and Theo Heller, M.D., Senior Investigator in the National Institute of Diabetes and Digestive and Kidney Diseases, joined David Fogel, a recent total gastrectomy patient, to discuss the latest advancements in treatment. The webinar, “Navigating New Treatment Options for Gastric Cancer: Reaching above and beyond the standard of care,” was facilitated by the NIH Clinical Center and Inspire, a social network for health that connects patients and caregivers in a safe, permission-based manner. Access the recorded webinar.

Members of NIH Foregut Team discuss new treatment options for stomach cancer
Prostate cancer

Clinical trial tests precision radiotherapy for recurrent prostate cancer

Posted: Dec 4, 2017

CCR investigators are leading a trial of stereotactic body radiation therapy (SBRT) to treat localized prostate cancer that has recurred after standard radiation therapy. The technique uses advanced molecular imaging to guide the delivery of high doses of radiation just to tumors that have recurred, potentially leading to fewer side effects. Read more…

Clinical trial tests precision radiotherapy for recurrent prostate cancer
Leukemia cells

New immunotherapy approach leads to remission in patients with the most common type of childhood cancer

Posted: Nov 30, 2017

Chimeric antigen receptor (CAR) T-cell immunotherapy has emerged as a promising treatment for pre-B cell acute lymphoblastic leukemia (B-ALL), the most common type of childhood cancer. B-ALL is characterized by an overproduction of immature white blood cells called lymphoblasts. In a trial led by Center for Cancer Research investigators, around 70 to 90 percent of patients whose B-ALL has relapsed or developed resistance to chemotherapy entered remission after CAR T-cell therapy targeting CD19. Read more…

New immunotherapy approach leads to remission in patients with the most common type of childhood cancer

Pages